Abstract 4140883: Human iPSCs and Human iPSC-Endothelial cells Derived from PAD Patients and Healthy Donors Have Similar Characteristics and Potency: Implications for Autologous Cell Therapy in Peripheral Artery Disease

Background: Peripheral artery disease (PAD) can lead to amputation in advanced cases, making cell therapy using human induced pluripotent stem cells (hiPSCs) a promising therapeutic option. hiPSC-derived endothelial cells (hiPSC-ECs) have shown favorable effects in treating experimental ischemic cardiovascular disease. An autologous approach for PAD patients is preferable to avoid immunological reactions. However, it is yet unknown whether hiPSCs and hiPSC-ECs derived from PAD patients have similar characteristics and potency compared to those derived from healthy volunteers. Therefore, we explored whether there are significant differences in the characteristics and potency of hiPSCs and hiPSC-ECs between non-PAD donors and PAD patients. Methods and Results: We successfully generated hiPSCs from the blood of seven non-PAD donors and eight PAD patients. Both non-PAD and PAD-derived hiPSCs exhibited similar expression levels of pluripotency markers, as determined by qRT-PCR, flow cytometry, and immunostaining. All hiPSCs, regardless of the group, formed teratomas and showed normal karyotypes. RNA-seq analyses revealed similar gene expression profiles between the groups. We then differentiated hiPSCs into endothelial cells (ECs) in a clinically compatible manner. hiPSC-ECs derived from both non-PAD and PAD donors exhibited similar expression levels of EC markers at both the gene (qRT-PCR) and protein levels (immunostaining and flow cytometry). RNA-seq analyses showed no significant overall differences in gene expression profiles between the groups. In vitro nitric oxide assays and tubular structure formation assays demonstrated similar endothelial characteristics and function in hiPSC-ECs from both groups. When injected into the hindlimb muscle following induction of hindlimb ischemia, both groups showed similar perfusion recovery, limb salvage, and vessel-forming capacity. Engrafted hiPSC-ECs from both groups also exhibited similar angiogenic and vessel-forming capabilities. Conclusions: Our study demonstrated no significant differences in hiPSCs and hiPSC-ECs derived from non-PAD donors and PAD patients in terms of molecular and cell biological characteristics, therapeutic effects, and vessel-forming capability. Our study indicates that hiPSCs and hiPSC-ECs derived from PAD patients can serve as a novel platform for autologous cell therapy.